Healthcare
DiaSorin S.p.A.(DSRLF)
Live Price
Offline$74.25
-11.71% today
1Y Change
-31.05%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $3.32B
- Revenue Growth
- +0.8%
- EPS Growth
- -20.5%
- Dividend Yield
- 1.9%
Coverage: 244 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
DiaSorin S.p.A. (DSRLF) is a Healthcare stock with a market cap of $3.32B and listed on OTC. The stock last traded around $74.25 and down 31.0% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +0.8%, EPS growth of -20.5%, a dividend yield of 1.9%. What stands out right now is revenue +0.8%, EPS -20.5%, free cash flow -14.2% with operating margin 26.5% and ROIC 11.8%. The dividend is present but secondary, with a yield around 1.9%. Valuation is more restrained than many high-expectation growth names at P/E 18.0 and price/sales 2.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines DSRLF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+0.8% vs +7.6% peer median
Operating Margin
Above sector median
+26.5% vs +19.4% peer median
P/E
Below sector median
18.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +0.8% and EPS is at -20.5%, with operating margin around 26.5%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.9%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +0.0% | +10.2% | +10.8% |
2026 Mar 20, 2026 | โ | -5.3% | -5.3% | +1.7% |
2025 Jul 31, 2025 | โ | +0.0% | +0.0% | -7.1% |
Benchmark Edge
DSRLF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
DSRLF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
DSRLF Max Drawdown
-38.10%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for DSRLF and SPY.
Company Overview
DiaSorin S.p.A.
Other OTC
DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.
- Leadership
- Carlo Rosa
- IPO Date
- Sep 11, 2009
- Employees
- 3.2k
- Street Address
- Via Crescentino snc
- Mailing
- Saluggia, VC, 13040
- Region
- Saluggia, VC, IT
- Reporting Currency
- USD
- Investor Line
- 39 01 614871
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 18.0
- EV/EBITDA
- 13.7
- Price/Sales
- 2.2
- Price/Book
- 2.2
Growth
- Revenue
- +0.8%
- EPS
- -20.5%
- Free Cash Flow
- -14.2%
Profitability
- Gross Margin
- 65.0%
- Operating Margin
- 26.5%
- Net Margin
- 13.1%
- ROE
- 12.0%
- ROIC
- 11.8%
Balance Sheet
- Debt/Equity
- 0.50
- Current Ratio
- 1.55
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.